Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
暂无分享,去创建一个
David C. Jones | P. Kearns | X. Paoletti | G. Vassal | A. Iasonos | C. Zwaan | D. Hawkins | S. Izraeli | J. Molenaar | G. Reaman | A. Mauguen | J. G. Glade Bender | F. Doz | B. Weigel | S. DuBois | M. Casanova | L. Moreno | L. Gore | K. Nysom | A. Pearson | Nick Bird | Vickie Buenger | E. Fox | S. Pfister | Malcolm Smith
[1] C. Pratilas,et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG) , 2022, Neuro-oncology.
[2] P. Kearns,et al. ACCELERATE - Five years accelerating cancer drug development for children and adolescents. , 2022, European journal of cancer.
[3] P. Hinds,et al. Recommended scoring approach for the pediatric patient‐reported outcomes version of the Common Terminology Criteria for Adverse Events , 2021, Pediatric blood & cancer.
[4] S. Raimondi,et al. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. , 2021, JAMA oncology.
[5] B. Morland,et al. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆ , 2021, ESMO open.
[6] N. André,et al. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. , 2021, European journal of cancer.
[7] K. Winter,et al. An Overview of Phase II Clinical Trial Designs. , 2021, International journal of radiation oncology, biology, physics.
[8] D. Wendler,et al. Do the Potential Medical Benefits of Phase 1 Pediatric Oncology Trials Justify the Risks? Views of the US Public. , 2021, The Journal of pediatrics.
[9] J. O'Quigley,et al. Randomised Phase 1 clinical trials in oncology , 2021, British Journal of Cancer.
[10] E. Eisenhauer,et al. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. , 2021, JAMA oncology.
[11] O. Hrusak,et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2021, JAMA.
[12] M. Loh,et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2021, JAMA.
[13] J. Fine,et al. Consistency of the CRM when the dose‐toxicity curve is not monotone and its application to the POCRM , 2021, Statistics in medicine.
[14] C. Bellera,et al. Optimal biological dose: a systematic review in cancer phase I clinical trials , 2021, BMC cancer.
[15] R. Bernards,et al. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. , 2020, The oncologist.
[16] J. Foster,et al. Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity , 2020, ESMO Open.
[17] B. Hobbs,et al. Histology-agnostic drug development — considering issues beyond the tissue , 2020, Nature Reviews Clinical Oncology.
[18] M. Ratain,et al. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. , 2020, Clinical pharmacology and therapeutics.
[19] R. Bernards,et al. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer , 2020, Cancer Chemotherapy and Pharmacology.
[20] R. Bernards,et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer , 2020, British Journal of Cancer.
[21] Cheng Cheng,et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2020, JAMA oncology.
[22] G. Armstrong,et al. Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. , 2020, JAMA oncology.
[23] J. Kimmelman,et al. Benefit, burden, and impact for a cohort of post-approval cancer combination trials , 2020, Clinical trials.
[24] J. Reid,et al. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411) , 2019, Pediatric blood & cancer.
[25] X. Paoletti,et al. Sequential or combined designs for Phase I/II clinical trials? A simulation study , 2019, Clinical trials.
[26] Herman Goossens,et al. Adaptive platform trials: definition, design, conduct and reporting considerations , 2019, Nature Reviews Drug Discovery.
[27] M. Ratain,et al. Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment. , 2019, JAMA oncology.
[28] Dylan V Neel,et al. Timing of first-in-child trials of FDA-approved oncology drugs. , 2019, European journal of cancer.
[29] Scott D Ramsey,et al. A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies , 2018, Journal of the National Cancer Institute.
[30] M. Loh,et al. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. , 2018, Future oncology.
[31] F. Peale,et al. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] Peter K. Sorger,et al. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.
[33] X. Paoletti,et al. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. , 2017, European journal of cancer.
[34] P. Hieter,et al. Synthetic lethality and cancer , 2017, Nature Reviews Genetics.
[35] S. Pfister,et al. Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective , 2017, Nature Reviews Clinical Oncology.
[36] Gudrun Schleiermacher,et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. , 2016, European journal of cancer.
[37] M. Schrappe,et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. , 2015, European journal of cancer.
[38] K. Stelzer,et al. A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001 , 2015, International Journal of Clinical Oncology.
[39] Andreas Schlicker,et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.
[40] N. Heerema,et al. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031 , 2014, Leukemia.
[41] A. Baruchel,et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. , 2013, European journal of cancer.
[42] John O'Quigley,et al. Dose-finding design for multi-drug combinations , 2011, Clinical trials.
[43] S. Joffe,et al. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? , 2008, Clinical trials.
[44] Sin-Ho Jung,et al. Randomized phase II trials with a prospective control , 2008, Statistics in medicine.
[45] D. Sargent,et al. Pick the winner designs in phase II cancer clinical trials. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[46] D. Frappaz,et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study , 2001, British Journal of Cancer.
[47] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[48] P F Thall,et al. An optimal three-stage design for phase II clinical trials. , 1994, Statistics in medicine.
[49] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.